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these reports may be the result of publication bias, i.e., it appears
that multiple groups have looked at this issue, but only those
groups that have found a signiﬁcant relationship, potentially as a
result of random chance, have reported their ﬁndings. To further
investigate this question we developed a multivariate logistic re-
gression model for factors predictive of acute GVHD based on a
series 167 patients, including 18 African-Americans, who under-
went allogeneic BMT at our institution between January 1, 1992
and May 30, 2004. Factors examined in the multivariate model
included age, CD34 dose, CD3 dose, sex mismatch pattern (fe-
male-to-male vs other), category of conditioning regimen (full-
dose vs reduced-dose), presence or absence of an antigen-level
HLA mismatch, type of donor (related vs unrelated), stem cell
source (marrow vs PBSC), and race (African-American vs Cauca-
sian). It was not possible to separate out the potential effect of the
GVHD prophylactic regimen because our data set is characterized
by a very strong correlation between type of GVHD prophylactic
regimen and category of conditioning regimen. We observed a
univariate trend toward an increased incidence of Grade 3 or
higher acute GVHD among African Americans (39% vs 21%, p 
0.13). Race was not independently predictive of acute GVHD in
the multivariate model, although the statistical power of the model
to detect this relationship was limited due to the fact that only 18
African Americans were included in the series. Interestingly,
among patients transplanted since 1996, there was a statistically
signiﬁcant (univariate) increase in the incidence of grade 3 or
higher acute GVHD among African Americans (64% vs 25%, p 
0.01) but also a parallel disparity in the incidence of HLA-mis-
matched transplantation (27% vs 6%, p  0.036) such that race
remained non-contributory in the multivariate model. We con-
clude that the purported relationship between race and acute
GVHD may be less strong that has been previously reported due to
publication bias and/or to an increased incidence of HLA-mis-
matched transplant in this population. Further examination of this
issue using larger data sets appears warranted.
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EXTRACORPOREAL PHOTOCHEMOTHERAPY FOR (ECP) THE TREAT-
MENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE
Couriel, D.R.; Hosing, C.; Anderlini, P.; Ippoliti, C.; Hsu, Y.; Neu-
mann, J.; De Lima, M.J.; Ghosh, S.; Rhodes, B.; Saliba, R.; Champlin,
R.; Donato, M. University of Texas M.D. Anderson Cancer Center,
Houston, TX.
Introduction: Chronic graft-versus-host disease (cGVHD) is a
major cause of long term morbidity and mortality following allo-
geneic hematopoietic stem cell transplant (HSCT). Beyond the
combination of steroids and calcineurin inhibitors, a variety of
immunosuppressive methods have been used to manage this con-
dition, most of them of limited efﬁcacy and steroid-sparing capac-
ity. ECP is becoming increasingly used in the treatment of acute
and chronic GVHD, with promising preliminary data. Methods:
Retrospective evaluation of all ECP procedures performed be-
tween 1/30/98 and 10/2/92 in patients with GVHD occurring after
day 100. Patients were considered evaluable for response when
they were treated with ECP for at least 1 month, without the
addition of any further immunosuppression. Complete (CR) and
partial responses (PR) had a minimal duration of 2 weeks. Results:
A total of 82 patients with chronic GVHD were analyzed. The
median age was 40 (5–70), and the donor origin was matched
sibling (48, 59%), matched unrelated (24, 29%) or mismatched
(10) HSCT. Most of them received tacrolimus-based prophylaxis
(74, 90%) and had a history of acute GVHD (64, 78%). Most
patients were on steroids (64) and had received a median of 2 (1–6)
treatments prior to ECP. Out of 82 patients, only 51 were evalu-
able for response, and the remainder received further immunosup-
pression within a month from the start of ECP (30), or lacked
documentation (1). The CR/PR rate for evaluable patients was
82% (n 42). Thirty-four patients (67%) had skin involvement
and the majority (32, 94%) responded to ECP. All types of skin
involvement (lichenoid, scleroderma, mixed, acute-appearing) re-
sponded to therapy. ECP also demonstrated activity in visceral
GVHD, with response rates of (15, 88%) and (6, 67%) respec-
tively. The CR/PR rate for oral GVHD was 100% (n 6), and for
ocular GVHD 75% (n 3). Of 51 patients, 32 required further
immunosuppression for control of their GVHD. Since initiation of
ECP, the overall survival for the whole group was 37%, with a
median survival of 10 months. Conclusions: In this heavily pre-
treated group of patients with chronic GVHD, the response to
ECP seems promising in all organs, including GVHD of the lung
and the liver. The prospective and systematic evaluation of the role
of ECP in the management of GVHD is warranted.
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SUBEROYLANILIDE HYDROXAMIC ACID MODULATES THE INNATE AND
ALLOSTIMULATORY RESPONSES OF DENDRITIC CELLS AND REGU-
LATES EXPERIMENTAL ACUTE GRAFT-VERSUS-HOST DISEASE
Reddy, P.1; Maeda, Y.1; Lowler, K.1; Liu, C.2; Dinarello, C.3; Ferrara,
J.L.M.1 1. University of Michigan Comprehensive Cancer Center, Ann
Arbor, MI; 2. University of Florida College of Medicine, Gainesville, FL;
3. University of Colorado Health Sciences Center, Denver, CO.
Dendritic cells modulate the innate (via Toll like receptors-
TLRs) and the allostimulatory immune responses. Suberoylanilide
hydroxamic acid (SAHA) is an anti-tumor agent that also exhibits
potent anti-inﬂammatory properties. We investigated the effect of
SAHA on modulating DC functions. Pre-incubation of BM de-
rived DCs with 100 nM-500 nM concentrations of SAHA (s-DCs)
signiﬁcantly reduced the secretion of TNF- and IL-6 upon TLR
stimulation with lipopolysaccharide (TLR-4), peptidoglycan
(TLR-2), poly IC (TLR-3) and CpG (TLR-9). Pre-treatment of
DCs with SAHA signiﬁcantly reduced the proliferation of alloge-
neic T cells in MLR cultures. Mixing experiments at 1:1 ratio
signiﬁcantly suppressed the allostimulatory capacity of control
DCs. Incubation of DCs with SAHA signiﬁcantly decreased the
expression of CD40, CD80, CD86 and OX40L and but caused no
signiﬁcant changes in MHC class II expression. We determined
the in vivo relevance of SAHA mediated effects on DCs by utilizing
Class I disparate CD8mediated [bm13 2MG/], and Class II
disparate CD4 mediated [bm12 3 MHC-II/] murine models
of alloreaction. Recipient 2MG/ and Class-II/ B6 animals
received 11 Gy, 2–4 106 T cells and 5 106 TCDBM cells from
syngeneic B6 or allogeneic bm-1 and bm-12 donors respectively.
The recipients were also injected on days1 and 0 with 4–5 106
wild type B6 BM derived c-DC and s-DCs. Injection of s-DCs
signiﬁcantly reduced in vivo allogeneic donor T cell expansion of
both CD4 and CD8 T cell subsets. We next utilized the well
characterized mouse [BALB/c 3 B6] model of acute GVHD to
determine the effect of s-DCs on an ongoing GVHD reaction. On
day1, the recipient B6 animals received 11 Gy and on day 0 were
injected with 2  106 T cells and 5  106 BM cells from syngeneic
B6 or allogeneic BALB/c donors. Injection of 5  106 host type
s-DCs on days 1, 0, and 2 resulted in signiﬁcantly better
survival, reduced serum levels of TNF-, donor T cell expansion
and histopathology of GVHD (P 
 0.01) on day 7 after BMT.
Lastly, we determined the effect of SAHA on the DCs derived
from the peripheral blood of normal healthy human volunteers and
found that SAHA signiﬁcantly reduced allogeneic T cell prolifer-
ation. Together our results demonstrate that SAHA modulates
innate and allostimulatory functions of DCs in vitro and in vivo,
and suggest that SAHA treatment of DCs might represent a novel
cellular therapy that can reduce clinical GVHD.
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MATURE T CELLS ALONE SEPARATE GVL FROM GVHD: THE NEED FOR
BETTER CONTROLS
Chen, B.J.; Son, J.; Cui, X.; Chao, N.J. Duke University Medical
Center, Durham, NC.
Separation of graft-vs.-leukemia effect (GVL) from graft-vs.-host
disease (GVHD) is the phenomenon that patients with leukemia/
lymphoma achieve complete remission without GVHD after allo-
geneic stem cell transplantation. We demonstrate in this study that
separation of GVL from GVHD could be achieved using only
unmanipulated mature T cells in a mouse model. Graded numbers
(103-106) of puriﬁed T cells from C57BL/6 mice were transplanted
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into lethally irradiated BALB/c mice along with 1  107 T cell
depleted bone marrow cells and 1  105 puriﬁed BCL1 cells (a
BALB/c-origin leukemia/lymphoma cell line). As a negative con-
trol, T cell depleted bone marrow alone rescued all lethally irra-
diated recipients and all survived more than 100 days after trans-
plantation without GVHD. All the recipients of T cell depleted
bone marrow and BCL1 cells developed tumor and died within 21
days post transplantation. Addition of 1  103 T cells in the graft
protected one out of ﬁve animals from developing tumor. Addition
of 1  104 T cells protected all recipients from developing tumor
and all survived more than 100 days after transplantation without
GVHD. Addition of both 1  105 and 1  106 protected all
animals from developing tumor. However, all animals in these two
groups developed GVHD and the majority died before 50 days
post transplantation. These data directly demonstrate that unma-
nipulated T cells alone can mediate GVL effect without causing
GVHD in a given animal model using a carefully titrated dose.
Based on these data, one can envision that separation of GVL from
GVHD may be achievable in a selected model by any approach
that is able to inhibit T cell function to a certain degree, speciﬁcally
or non-speciﬁcally. Knowledge of this information is important in
all animal models testing different approaches for the prevention of
GVHD without loss of GVL. Unfortunately, separation of GVL
from GVHD is very difﬁcult to achieve in humans by using
unmanipulated T cells alone due to unknown minimum dose
required for induction of GVHD in individual patients. Therefore,
in order to translate the ﬁndings into human setting, it will be
important to determine not only whether separation of GVL from
GVHD is achievable but also how wide the therapeutic window is.
The therapeutic window will help to determine whether the ap-
proach is translatable in humans or not.






SurvivalDay 21 Day 98
TCD BM alone — 18.6  0.9 19.1  2.1 5/5
TCDBM BCL1 5/5 14.7  0.8* — 0/5
1  103 4/5 16.7  2.1* 15.0  0.0 1/5
1  104 0/5 18.5  1.1* 18.7  2.0 5/5
1  105 0/5 15.7  1.6* 14.7  3.2* 2/5
1  106 0/5 14.9  0.9* — 0/5
*P 
 0.05, compared with TCD BM alone.
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CC CHEMOKINE RECEPTOR 2 IS INVOLVED IN INTESTINAL HOMING OF
ALLOREACTIVE DONOR CD8 T CELLS DURING GVHD
Terwey, T.H.; Kochman, A.A.; Eng, J.M.; Hubbard, V.M.; Muriglan,
S.J.; Waldman, E.D.; Zakrzewski, J.L.; Alpdogan, O.; van den Brink,
M.R.M. Memorial Sloan-Kettering Cancer Center, New York, NY.
Chemokines and chemokine receptors play an important role in
T cell homing and T cell mediated diseases, such as graft-versus-
host disease (GVHD). In a series of experiments using DNA
microarrays and ELISA analysis we found that monocyte chemoat-
tractant protein-1 (MCP-1) is upregulated in GVHD target organs
in the ﬁrst two weeks after bone marrow transplantation (BMT).
CC Chemokine Receptor 2 (CCR2) is the primary receptor for
MCP-1 and is expressed on a variety of hematopoietic cells includ-
ing monocytes, macrophages and memory T cells. The relevance
of CCR2 for homing of monocytes and macrophages has been
demonstrated in a variety of disease models but data on the rele-
vance of CCR2 for T cell homing are limited. Therefore, we
analyzed the effects of CCR2-deﬁciency on the homing capacity of
donor T cells in clinically relevant murine GVHD models. We
ﬁrst demonstrated that proliferation, alloactivation, IFN- produc-
tion and cytotoxicity of B6.CCR2/T cells were intact. However,
preliminary studies with a donor T cell inoculum consisting of
50% B6.WT and 50% B6.CCR2/ T cells showed a reduced
inﬁltration of B6.CCR2/ donor CD8 T cells into the intestinal
epithelium of C3FeB6F1 recipients. Homing to other organs and
homing of CD4 T cells was not impaired. In accordance with
these ﬁndings we could demonstrate a reduction of GVHD mor-
bidity and mortality in recipients of B6.CCR2/ CD8 T cells
while preliminary data showed no major difference for CD4 T
cells. Recipients of B6.CCR2/ CD8 T cells had a signiﬁcant
reduction in large intestine histopathology scores and showed a
trend towards lower scores for the small intestine. Moreover, the
graft-versus-tumor (GVT) activity of B6.CCR2/ CD8 T cells
against P815 mastocytoma in B6D2F1 recipients was intact, as
demonstrated by in vivo bioluminescent imaging. Again GVHD
mortality was reduced for B6D2F1 recipients of B6.CCR2/
CD8 T cells. In conclusion, our data suggest that the MCP-1-
CCR2 pathway is involved in intestinal homing of alloreactive T
cells during GVHD but is not essential for GVT activity.
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RISK FACTORS FOR THE DEVELOPMENT OF ACUTE AND CHRONIC
GVHD AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION IN CHILDREN AND ADOLESCENTS
Peters, C.1; Lawitschka, A.1; Atarbaschi, A.1; Fritsch, G.2; Lion, T.2;
Rosenmayr, A.3; Fischer, G.4; Hoecker, P.4; Gadner, H.1; Matthes-
Martiin, S.1 1. St. Anna Children’s Hospital, Vienna, Austria; 2.
Children Cancer Research Institute, Vienna, Austria; 3. Austrian Stem
Cell Registry, Vienna, Austria; 4. University Clinic for Blood Group
Serology and Transfusion Medicine, Vienna, Austria.
Children and adolescents undergoing hematopoietic SCT have
to be protected from the deteriorating side effects of severe acute
and chronic GvHD which impairs quality of life and causes severe
long lasting acute and late effects. To analyse which risk factors are
of importance for the development of GvHD in young patients we
analysed 297 pediatric recipients of allogeneic stem cell transplants
at a single centre between 1993 and 2003. We evaluated the
inﬂuence of patient/donor sex, age, CMV status, disease and dis-
ease status, donor type, graft manipulation, use of monoclonal
antibodies or ATG, conditioning regimen, HLA-matching tech-
niques, year of transplantation and the number and source of
transplanted stem cells. The results showed an association of dis-
ease status (advanced malignancies vs. early stages), donor type
(unrelated vs. sibling), year of SCT (before vs. after 1997) and
HLA-typing methods (high resolution techniques vs. serological
typing) with an increased relative risk (RR) of aGvHD. Increased
risk of cGvHD was associated with non T-cell depleted (TCD)
PBSCT from UD, patient’s age 15 years, transplantation before
1997 and evidence of aGvHD. No signiﬁcant inﬂuence for the
development of aGvHD/cGvHD was found for TBI vs non TBI-
containing regimen, use of ATG, or myeloablative vs. non myeloa-
blative conditioning regimen, respectively. Furthermore, donor’s
age, gender, underlying disease (malignant vs. non malignant dis-
orders) and number of transplanted stem cells did not signiﬁcantly
inﬂuence the severity of aGVHD/cGVHD. However, in a Cox
Regression analysis with time dependent covariates treatment re-
lated mortality was higher in patients with malignancies when
transplanted at an advanced disease status or in CMV- IgG pos pts
receiving stem cells from a CMV-negative donor. Interestingly,
the overall and disease free survival in pts with malignant diseases
was similar with no, mild or severe aGvHD (5-yrs pSU: 0.67, 0.74
and 0.65) Our data support the preferential selection of CMV-pos
donors for CMV-pos recipients and the consideration of HLA-
typing with high resolution techniques to apply an appropriate
GvHD-prophylaxis according to the identiﬁed HLA disparities.
Furthermore, patients with high risk leukemia might beneﬁt from
allogeneic SCT at an early remission stage. Children with non-
malignant disorders can be treated with reduced intensity condi-
tioning without signiﬁcant higher risk of acute or chronic GvHD,
respectively.
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